Stock Groups

WHO expecting more info as it weighs approving India’s Covaxin for COVID-19 By Reuters

by Mike Robinson

[ad_1]

2/2
© Reuters. FILEPHOTO: India’s Bharat Biotech office is seen as a man riding his motorcycle past the parked vehicle of Bharat Biotech. This was July 3, 2020 in Hyderabad. REUTERS/Stringer

2/2

BENGALURU (Reuters), – On Monday, the World Health Organization stated that it expected Bharat Biotech’s COVID-19 vaccine information to be available. It is a blow to Indian pharmaceutical company’s efforts to obtain an emergency-use list for the shot.

The two-dose Covaxin vaccine is not likely to be approved by WHO without their approval. Bharat Biotech, which has provided data continuously since July on a rolling basis to WHO for an emergency-use registration, is actively pursuing this listing.

“We know that people want (Bharat Biotech’s) Covaxin included in #COVID19’s Emergency Use List, but we can’t cut corners,” WHO stated on Twitter.

Bharat Biotech didn’t immediately reply to a Reuters inquiry for comment.

Covaxin, one of three vaccines approved for use in India’s adult vaccination drive is used. A total of 30% of India’s 944 million eligible adult population have been fully immunized, with more than 112,000,000 Covaxin doses administered.

“Bharat Biotech… has been sending data to WHO on an ongoing basis, and WHO experts have examined these data. WHO has one more piece from the company today, the global healthcare agency stated on Twitter.

Soumya Swaminathan (whole body’s chief scientist) stated that on Sunday, the Technical Advisory Group of WHO met on October 26 to review the Covaxin listing.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]